Lichieh Julie Chu

朱俐潔 (Lichieh Julie Chu)

Appointment:Assistant Professer

Lab: Multi-omics and Precision Medicine Laboratory

Education: Ph.D.

University/Nation: National Yang Ming University/Taiwan

Tel: 3557

E-mail: julie.chu@mail.cgu.edu.tw

Research website:

Research interests:

Precision medicine has become an important strategy for detection and monitoring of diseases. In our lab, multi-omics data is integrated using concepts of systems biology to classify patients’ groups based on considering of variation among individuals. We also use single cell omics technique to deal with the heterogeneity of cancer lesions and improve understanding of disease mechanisms. Besides, the roles of extracellular vesicles (EVs, including exosome) in disease progression are also explored. More than that, mutual comparison and verification using multi-omics data help us find proper biomarkers to verify in clinical specimens.

For implementing of disease surveillance, a good biomarker should be not only highly discriminating diseases, but non-invasive, simple and rapid detection. We have designed the collection of clinical specimens (including body fluids) depends on characteristics of diseases, and build a system to fully record their information as well as clinical outcomes. The selected potential biomarker candidates are verified using the large cohort of body fluid specimens, and develop their detection reagents as our final goal.

Now we focus on:

  1. analyzing high-risk oral precancerous and cancerous lesions using multi-omics and single-cell omics technologies to clarify the process of malignant transformation from precancer to cancer.
  2. exploring the roles of EVs in the process of oral cancer carcinogenesis, and also finding out the membrane protein biomarkers on EVs for verifying their effectiveness in a large cohort of saliva samples.

Publications (Recent 5 years):

  1. Lee YC, Wong WT, Li LH, Chu LJ, Menon MP, Ho CL, Chernikov OV, Lee SL, Hua KF. (2020) Ginsenoside M1 Induces Apoptosis and Inhibits the Migration of Human Oral Cancer Cells. Int J Mol Sci 21(24):E9704
  2. Chang YT, Chu LJ, Liu YC, Chen CJ, Wu SF, Chen CH, Chang IY, Wang JS, Wu TY, Dash S, Chiang WF, Chiu SF, Gou SB, Chien CY, Chang KP, Yu JS. (2020) Verification of saliva matrix metalloproteinase-1 as a strong diagnostic marker of oral cavity cancer. Cancers 12(8):2273
  3. Yang SR, Hua KF, Chu LJ, Hwu YK, Yang SM, Wu CY, Lin TJ, Wang JC, Zhao H, Hsu WH, Liu FC, Liaw WJ, Ma D, Ka SM, Chen A. (2020) Xenon blunts NF-κB/NLRP3 inflammasome activation and improves acute onset of accelerated and severe lupus nephritis in mice. Kidney Int S0085-2538(20)30357-4
  4. Lin HC, Chu LJ, Huang PJ, Cheng WH, Zheng YH, Huang CY, Hong SW, Chen LC, Lin HA, Wang JY, Chen RM, Lin WN, Tang P, Huang KY. (2020) Proteomic signatures of metronidazole-resistant Trichomonas vaginalis reveal novel proteins associated with drug resistance. Parasit Vectors 13(1):274
  5. Wu CY, Hua KF, Hsu WH, Suzuki Y, Chu LJ, Lee YC, Takahata A, Lee SL, Wu CC, Nikolic-Paterson DJ, Ka SM, Chen A. (2020) IgA Nephropathy Benefits from Compound K Treatment by Inhibiting NF-κB/NLRP3 Inflammasome and Enhancing Autophagy and SIRT1. J Immunol 205(1):202-212
  6. Hsiao YC, Lin SY, Chien KY, Chen SF, Wu CC, Chang YT, Chi LM, Chu LJ, Chiang WF, Chien CY, Chang KP, Chang YS, Yu JS. (2020) An immuno-MALDI mass spectrometry assay for the oral cancer biomarker, matrix metalloproteinase-1, in dried saliva spot samples. Anal Chim Acta 1100:118-130
  7. Hsu WH, Hua KF, Tuan LH, Tsai YL, Chu LJ, Lee YC, Wong WT, Lee SL, Lai JH, Chu CL, Ho LJ, Chiu HW, Hsu YJ, Chen CH, Ka SM, Chen A. (2020) Compound K inhibits priming and mitochondria-associated activating signals of NLRP3 inflammasome in renal tubulointerstitial lesions. Nephrol Dial Transplant. 35(1):74-85
  8. Chi LM, Hsiao YC, Chien KY, Chen SF, Chuang YN, Lin SY, Wang WS, Chang IY, Yang C, Chu LJ, Chiang WF, Chien CY, Chang YS, Chang KP, Yu JS. (2020) Assessment of candidate biomarkers in paired saliva and plasma samples from oral cancer patients by targeted mass spectrometry. J Proteomics 211:103571
  9. Ho ML*, Kuo WK*, Chu LJ*, Yeh IH, Fan CW, Chang HI, Yuan CL, Chou TU, Chen HY, Yang SW, Chang LC, Luo MZ, Wu TH, Chang YI, Yu CJ, Hua CC, Ng WV. (2019) N-acetylgalactosamine-6-sulfatase (GALNS), similar to glycodelin, is a potential general biomarker for multiple malignancies. Anticancer Res. 39(11):6317-6324 (Ho ML, Kuo WK & Chu LJ - equal contribution)
  10. Lin WC, Tsai CY, Huang JM, Wu SR, Chu LJ, Huang KY. (2019) Quantitative proteomic analysis and functional characterization of Acanthamoeba castellanii exosome-like vesicles. Parasit Vectors. 12(1):467
  11. Fan PC, Chen CC, Peng CC, Chang CH, Yang CH, Yang C, Chu LJ, Chen YC, Yang CW, Chang YS, Chu PH. (2019) A circulating miRNA signature for early diagnosis of acute kidney injury following 123453456acute myocardial infarction. J Transl Med. 30;17(1):139
  12. Chen YT, Huang HC, Hsieh YJ, Fu SH, Li L, Chen CL, Chu LJ, Yu JS. (2019) Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers. J Food Drug Anal. 27(2):460-474
  13. Chu LJ*, Hsiao YC, Chiang WF, Tsai CJ, Lin SY, Chang KP, Chien CY, & Yu JS. (2018) Use of saliva protein biomarkers for diagnosis of oral cavity cancer. International Journal of Head and Neck Science. 2(2):56-68
  14. Huang YW, Chiang MF, Ho CS, Hung PL, Hsu MH, Lee TH, Chu LJ, Liu H, Tang P, Ng WV, & Lin DS. (2018) A transcriptome study of progeroid neurocutaneous syndrome reveals POSTN as a new element in proline metabolic disorder. Aging and Disease. 9(6):1043-1057
  15. Hsiao YC*, Chu LJ*, Chen YT, Chi LM, Chien KY, Chiang WF, Chang YT, Chen SF, Wang WS, Chuang YN, Lin SY, Chang YS, & Yu JS. (2018) Variability assessment of 90 salivary proteins in intra-day and inter-day samples from healthy donors by multiple reaction monitoring-mass spectrometry. Proteomics Clin Appl. 12(2) (Hsiao YC & Chu LJ - equal contribution)
  16. Lai YH, Liu H, Chiang WF, Chen TW, Chu LJ, Yu JS, Chen SJ, Chen HC, Tan BC. (2018) MiR-31-5p-ACOX1 Axis Enhances Tumorigenic Fitness in Oral Squamous Cell Carcinoma Via the Promigratory Prostaglandin E2. Theranostics. 8(2):486-504
  17. Chen TW, Lee CC, Liu H, Wu CS, Pickering CR, Huang PJ, Wang J, Chang IY, Yeh YM, Chen CD, Li HP, Luo JD, Tan BC, Chan TEH, Hsueh C, Chu LJ, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW, See LC, Tang P, Yu JS, Liao WC, Chiang WF, Rodriguez H, Myers JN, Chang KP, Chang YS. (2017) APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. Nat Commun. 8(1):465-657.
  18. Hsiao YC*, Chu LJ*, Chen JT, Yeh TS, & Yu JS. (2017) Proteomic profiling of the cancer cell secretome: informing clinical research. Expert Rev Proteomics. 14(9):737-756 (Hsiao YC & Chu LJ - equal contribution)
  19. Hsiao YC, Chi LM, Chien KY, Chiang WF, Chen SF, Chuang YN, Lin SY, Wu CC, Chu LJ, Chen YT, Chia SL, Chien CY, Chang KP, Chang YS, & Yu JS. (2017) Development of a multiplexed assay for oral cancer candidate biomarkers using peptide immunoaffinity enrichment and targeted mass spectrometry. Mol Cell Proteomics. 16(10):1829-1849
  20. Chen YT, Chen HW, Wu CF, Chu LJ, Chiang WF, Yu JS, & Chang YS. (2017) Development of a Multiplexed LC-MRM MS Method of Salivary Proteins for Evaluation of Oral Cancer Biomarkers. Mol Cell Proteomics. 16(5):799-811
  21. Lin YT, Chien KY, Wu CC, Chang WY, Chu LJ, Yeh CT, & Yu JS. (2017) Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma. J Proteomics. 57:40-51
  22. Yu JS*, Chen YT*, Chiang WF*, Hsiao YC*, Chu LJ*, See LC, Wu CS, Tu HT, Chen HW, Chen CC, Liao WC, Chang YT, Wu CC, Lin CY, Liu SY, Chiou ST, Cha SL, Chang KP, Chien CY, Chang SW, Chang CJ, Young JD, Pao CC, Chang YS, & Hartwell LH. (2016) Saliva Protein Biomarkers to Detect Oral Squamous Cell Carcinoma in a High-Risk Population in Taiwan. Proc Natl Acad Sci USA. 113(41):11549-54 (Yu JS, Chen YT, Chiang WF, Hsiao YC & Chu LJ - equal contribution)